비호지킨림프종 치료 시장 : 치료법별, 세포 유형별, 투여 경로별, 환자 연령층별, 최종 사용자별 시장 예측(2026-2032년)

The Non-Hodgkin Lymphoma Treatment Market is projected to grow by USD 18.28 billion at a CAGR of 9.12% by 2032.

Non-Hodgkin Lymphoma Treatment Market Introduction

Non-Hodgkin lymphoma (NHL) treatment is moving from broad chemoimmunotherapy toward biomarker-guided, immune-based, and cellular therapy strategies. The disease group spans more than 60 biologically distinct lymphoid malignancies, with diffuse large B-cell lymphoma and follicular lymphoma among the most common subtypes. According to IARC GLOBOCAN 2022, NHL accounted for more than 550,000 new cancer cases and roughly 250,000 deaths globally, underscoring the need for earlier diagnosis, durable remission, and wider access to advanced therapies.

Market momentum is supported by established anti-CD20 monoclonal antibodies, antibody-drug conjugates, BTK inhibitors, selective kinase inhibitors in defined settings, CAR T-cell therapies, and CD20xCD3 bispecific antibodies. Treatment decisions increasingly depend on histology, stage, age, performance status, prior therapy, molecular risk, comorbidities, treatment intent, and access to specialized care infrastructure.

Transformative Shifts in the NHL Treatment Landscape

The NHL treatment landscape has undergone a structural shift as clinicians move beyond one-size-fits-all chemotherapy. Rituximab-based regimens remain foundational for many B-cell lymphomas, while newer agents such as antibody-drug conjugates, immunomodulatory combinations, bispecific antibodies, and CAR T-cell products have expanded options for relapsed or refractory disease. Regulatory decisions in the United States, Europe, Japan, China, and other major markets show increasing acceptance of subtype-specific evidence, accelerated pathways for high-unmet-need disease, and post-authorization requirements for longer-term safety and durability data.

This transformation is changing care pathways. Community oncology networks are managing more complex sequencing decisions, academic centers are scaling cellular therapy programs, and payers are scrutinizing real-world durability, toxicity management, and total cost of care. The next competitive frontier is not only efficacy but also outpatient feasibility, manufacturing reliability, minimal residual disease assessment, cytokine release syndrome management, neurotoxicity monitoring, and equitable access to advanced lymphoma treatment.

Cumulative Impact of Artificial Intelligence on NHL Care

Artificial intelligence is creating cumulative value across NHL diagnosis, treatment selection, clinical operations, and post-treatment monitoring. In pathology, AI-assisted image analysis can support lymphoma classification, proliferation scoring, and workflow triage, while radiomics and machine learning can enhance PET/CT interpretation and response assessment when validated against clinical standards such as Lugano criteria and established nuclear medicine practice.

AI is also improving trial matching, adverse event surveillance, pharmacovigilance, and real-world evidence generation by organizing structured and unstructured clinical data. Large language models and clinical decision-support tools can reduce administrative burden, but adoption must remain governed by data quality, bias testing, clinical validation, cybersecurity, explainability, and transparent oversight. In NHL, AI's strongest near-term impact is expected where it complements hematopathologists, radiologists, pharmacists, and multidisciplinary tumor boards rather than replacing specialist judgment.

Key Regional Insights Across Global NHL Treatment Markets

North America remains a major innovation hub for NHL treatment because of strong oncology research funding, FDA-enabled accelerated approvals, CAR T-cell center capacity, and broad participation in cooperative group trials. The United States drives much of the clinical adoption of bispecific antibodies and cellular therapy, while Canada emphasizes evidence review, provincial reimbursement decisions, and standardized cancer agency pathways. Europe combines high clinical sophistication with cost-effectiveness scrutiny, especially across EU health technology assessment systems. The United Kingdom, Germany, France, Italy, and Spain support advanced lymphoma care, although reimbursement timing, hospital capacity, and access to CAR T-cell slots vary across countries.

Asia-Pacific is expanding rapidly as China, Japan, South Korea, India, and Australia increase clinical trial activity, local biologics capacity, lymphoma guideline adoption, and access to targeted therapies. Latin America shows rising demand as Brazil and Mexico strengthen oncology services, but diagnosis, reimbursement, and access to advanced agents remain concentrated in metropolitan centers. The Middle East, particularly wealthier Gulf health systems, is investing in tertiary oncology infrastructure, precision diagnostics, and specialist referral pathways. Africa faces the widest access gaps, with late diagnosis, limited hematopathology capacity, affordability constraints, and uneven availability of essential cancer medicines making biosimilars, regional centers of excellence, telepathology, and public-sector oncology programs central to improving NHL treatment outcomes.

Key Group Insights for NHL Treatment Strategy

Within ASEAN, demand is shaped by population growth, expanding private hospital networks, medical travel, and uneven access to molecular diagnostics and advanced immunotherapies. Singapore, Thailand, and Malaysia act as regional care anchors, while broader ASEAN access depends on affordability, public procurement, biosimilar uptake, and hematology workforce expansion. The GCC is investing in tertiary oncology infrastructure, precision medicine, digital health, and referral pathways for complex lymphoma cases, supporting adoption of immunotherapies where reimbursement and specialist capacity are available.

The European Union offers a highly regulated but attractive environment where centralized drug approvals, evolving joint clinical assessment, pharmacovigilance standards, and national reimbursement systems influence launch sequencing. BRICS economies combine large patient pools with increasing domestic manufacturing, biosimilar development, and clinical trial participation, though access remains differentiated by income, region, and public insurance coverage. G7 countries remain central to R&D, regulatory precedent, guideline development, and premium therapy adoption. NATO countries overlap substantially with high-income Western markets, where oncology resilience, medicine supply security, cross-border research collaboration, and preparedness planning are increasingly strategic for uninterrupted NHL care.

Key Country Insights Shaping NHL Treatment Demand

The United States is the largest high-value NHL treatment market, supported by deep clinical trial networks, early adoption of CAR T-cell therapy and bispecific antibodies, comprehensive cancer centers, and strong specialty pharmacy infrastructure. Canada offers high-quality care through provincial systems but often experiences more deliberate reimbursement timelines and regional variation in access to advanced therapies. Mexico and Brazil face a growing lymphoma burden and improving oncology capacity, though access to molecular testing, cellular therapy, and novel biologics remains concentrated in major urban centers and private systems.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature hematology practice with payer-driven evidence requirements. Germany often provides early post-approval access under structured reimbursement processes, while the United Kingdom uses health technology assessment to determine NHS adoption. France, Italy, and Spain maintain strong lymphoma networks but balance innovation with budget impact and regional implementation. Russia has substantial clinical need but faces access variability, procurement complexity, and uneven availability of newer therapies. China is advancing rapidly through local innovation, domestic biologics, hospital expansion, and large-scale trial participation; India combines high unmet need with affordability constraints, diagnostic variability, and biosimilar opportunity. Japan, Australia, and South Korea are sophisticated markets with strong regulatory systems, high diagnostic standards, active clinical research, and growing use of targeted and immune-based NHL therapies.

Actionable Recommendations for NHL Industry Leaders

Industry leaders should prioritize evidence packages that demonstrate durable remission, safety, quality of life, treatment sequencing value, and health-system relevance across defined NHL subtypes. Real-world evidence should be built into launch planning, particularly for CAR T-cell therapies, bispecific antibodies, antibody-drug conjugates, and therapies moving into earlier lines of treatment.

Manufacturers, providers, and payers should expand partnerships that improve diagnostic accuracy, accelerate referral to lymphoma specialists, and enable outpatient administration where clinically appropriate. Investments in biosimilars, patient assistance, local manufacturing, cold-chain reliability, adverse event management training, and digital care coordination can widen access in cost-sensitive markets while preserving clinical quality and continuity of care.

Research Methodology

This executive summary is grounded in secondary research from recognized oncology and public health sources, including IARC GLOBOCAN, WHO resources, national cancer agencies, regulatory approval databases, peer-reviewed hematology literature, and established clinical guideline bodies such as NCCN, ESMO, ASH, and disease-specific lymphoma consensus publications.

The analysis synthesizes disease epidemiology, treatment innovation, regional access dynamics, reimbursement patterns, regulatory pathways, diagnostic infrastructure, and adoption barriers. Insights were assessed for consistency across credible sources, with emphasis on verifiable clinical developments, approved therapeutic classes, observable access trends, and published medical evidence rather than unsupported projections, market sizing, or forecast-based assumptions.

Conclusion: Strategic Outlook for NHL Treatment

Non-Hodgkin lymphoma treatment is entering a more precise and competitive era defined by immunotherapy, cellular therapy, targeted agents, biosimilars, and AI-enabled care optimization. The strongest opportunities will emerge where clinical innovation aligns with diagnostic capacity, reimbursement evidence, manufacturing reliability, specialist training, toxicity management, and equitable delivery.

Organizations that combine robust clinical differentiation with access-focused execution will be best positioned to support sustainable growth while improving outcomes for patients across mature and emerging oncology markets. As NHL care becomes increasingly personalized, success will depend on turning scientific progress into timely, affordable, and high-quality treatment pathways.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type

• 7.1. Chemotherapy
• 7.2. Immunotherapy
• 7.3. Radiation Therapy
• 7.4. Stem Cell Transplant
• 7.5. Targeted Therapy

8. Non-Hodgkin Lymphoma Treatment Market, by Cell Type

• 8.1. B-cell Lymphomas
  • 8.1.1. Burkitt Lymphoma
  • 8.1.2. Diffuse Large B-Cell Lymphoma (DLBCL)
  • 8.1.3. Follicular Lymphoma
  • 8.1.4. Mantle Cell Lymphoma
  • 8.1.5. Marginal Zone Lymphoma
• 8.2. NK-cell Lymphomas
• 8.3. T-cell Lymphomas
  • 8.3.1. Anaplastic Large Cell Lymphoma
  • 8.3.2. Cutaneous T-Cell Lymphoma
  • 8.3.3. Peripheral T-Cell Lymphoma

9. Non-Hodgkin Lymphoma Treatment Market, by Route of Administration

• 9.1. Intravenous Infusion
• 9.2. Oral
• 9.3. Subcutaneous Injection

10. Non-Hodgkin Lymphoma Treatment Market, by Patient Age Group

• 10.1. Adult
• 10.2. Geriatric
• 10.3. Pediatric

11. Non-Hodgkin Lymphoma Treatment Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Cancer Treatment Centers
• 11.3. Hospitals

12. Non-Hodgkin Lymphoma Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Non-Hodgkin Lymphoma Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Non-Hodgkin Lymphoma Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AbbVie Inc.
• 16.2. AstraZeneca PLC
• 16.3. Bayer AG
• 16.4. BeiGene, Ltd.
• 16.5. Bristol-Myers Squibb Company
• 16.6. Cipla Inc.
• 16.7. Dr. Reddy's Laboratories Ltd.
• 16.8. Eli Lilly and Company
• 16.9. F. Hoffmann-La Roche Ltd
• 16.10. Gilead Sciences, Inc.
• 16.11. GlaxoSmithKline PLC
• 16.12. Hikma Pharmaceuticals PLC
• 16.13. Intas Pharmaceuticals Ltd.
• 16.14. Kyowa Kirin Co., Ltd.
• 16.15. Lupin Ltd.
• 16.16. Merck & Co., Inc.
• 16.17. Novartis AG
• 16.18. Salvavidas Pharmaceutical Pvt. Ltd.
• 16.19. Sanofi S.A.
• 16.20. Takeda Pharmaceutical Company Limited
• 16.21. Teva Pharmaceutical Industries Ltd.
• 16.22. Zydus Pharmaceuticals